Operose Advisors’s Viking Therapeutics VKTX Stock Holding History

Operose Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$184K	Hold	4,714	–	–	0.04%	180
2026 Q1	$153K	Hold	4,714	–	–	0.04%	173
2025 Q4	$166K	Buy	+4,714	New	+$167K	0.04%	168

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Operose Advisors's VKTX Position: Q2 2026 in Review

Operose Advisors held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 4,714 shares worth $184K. The position accounts for 0.04% of the portfolio, ranked #180.

Operose Advisors first reported a position in VKTX in Q4 2025 and has held it in 3 quarters since. 434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Operose Advisors held 4,714 shares of Viking Therapeutics worth $184K as of Q2 2026.
Operose Advisors left its Viking Therapeutics share count unchanged in Q2 2026.
Viking Therapeutics made up 0.04% of Operose Advisors's portfolio in Q2 2026, its #180 holding.
Operose Advisors first reported a position in Viking Therapeutics in Q4 2025 and has held it in 3 quarters since.
434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Operose Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.